Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amarin Corporation plc - American Depositary Shares (NQ:AMRN)

16.81 +0.59 (+3.64%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amarin Corporation plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
Amarin Announces Two Upcoming Investor Events
From Amarin Corporation plc
Via GlobeNewswire
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual
From Amarin Corporation plc
Via GlobeNewswire
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
From Amarin Corporation plc
Via GlobeNewswire
Amarin Plc (AMRN) Q2 2024 Earnings Call Transcript
AMRN earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
3 Breakthrough Stocks Under $10 Set for Massive Upside
Discover the top breakthrough stocks under $10 with strong fundamentals and strategic advantages to hit massive upside. 
Via InvestorPlace
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
From Amarin Corporation plc
Via GlobeNewswire
Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
From Amarin Corporation plc
Via GlobeNewswire
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides. 
Via Investor's Business Daily
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Amarin Board of Directors Announces CEO Transition
From Amarin Corporation plc
Via GlobeNewswire
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
From Amarin Corporation plc
Via GlobeNewswire
AMRN Stock Earnings: Amarin Corp Beats EPS, Misses Revenue for Q1 2024
AMRN stock results show that Amarin Corp beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Amarin Plc (AMRN) Q1 2024 Earnings Call Transcript
AMRN earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Amarin Reports First Quarter 2024 Business Update and Financial Results
From Amarin Corporation plc
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect Patients 
From Amarin Corporation plc
Via GlobeNewswire
Amarin Announces Results of Annual General Meeting of Shareholders
- Shareholders Approve Share Repurchase Program of up to $50 Million - 
From Amarin Corporation plc
Via GlobeNewswire
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
From Amarin Corporation plc
Via GlobeNewswire
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action 
From Amarin Corporation plc
Via GlobeNewswire
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
From Amarin Corporation plc
Via GlobeNewswire
Why Amarin Stock Was Rocketing Higher on Wednesday
There was unambigously good news about the company's single commercialized medication. 
Via The Motley Fool
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
Company’s IP Protection for VAZKEPA® in Europe Now Extended Into 2039 
From Amarin Corporation plc
Via GlobeNewswire
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
From Amarin Corporation plc
Via GlobeNewswire
Amarin Plc (AMRN) Q4 2023 Earnings Call Transcript
AMRN earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Why Is Amarin Stock Trading Lower After Q4 Earnings?
Amarin's Q4 2023 financials: Revenues at $74.71 million, beating consensus. US net product revenue is $64.9 million, down Y/Y. CEO Patrick Holt shares operational progress, including European market... 
Via Benzinga
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.